REYON PHARMACEUTICAL CO., LTD Logo

REYON PHARMACEUTICAL CO., LTD

Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.

102460 | KO

Overview

Corporate Details

ISIN(s):
KR7102460003
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로 620 에이동 12층 (대치동, 미래에셋타워), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Reyon Pharmaceutical Co., Ltd. is an integrated pharmaceutical company focused on the research, development, and manufacturing of both chemical and biopharmaceutical products. The company's core business includes the production of Active Pharmaceutical Ingredients (APIs) and finished generic formulations, such as injections, tablets, and antibiotics. Strategically expanding into next-generation therapeutics, Reyon is actively developing advanced treatments in areas like AAV gene therapy for conditions such as wet age-related macular degeneration (wAMD) and NK cell therapy for solid cancers. A significant part of its growth strategy involves its biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services, which are being scaled through strategic partnerships to support the production of complex biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.5 MB
2025-08-01 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-07-25 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 12.2 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 92.2 KB
2025-06-02 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.8 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.6 MB
2025-04-25 00:00
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Korean 10.9 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.3 KB
2025-03-24 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.1 MB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 20.0 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 629.3 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 14.8 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 1.1 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 1.0 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.9 KB

Automate Your Workflow. Get a real-time feed of all REYON PHARMACEUTICAL CO., LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for REYON PHARMACEUTICAL CO., LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for REYON PHARMACEUTICAL CO., LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.